What's New in eCTD Module 1 Regional Specifications for the US and EU in 2025?

Module 1 for the eCTD has been updated in both the US and EU during 2024 and 2025 with clearer validation criteria, controlled vocabularies, and machine-readable metadata to support the gradual global shift to eCTD v4.0. EMA enforced EU M1 v3.1 validation criteria v8.0 from 1 March 2025, requiring sponsors to update submission packaging. The FDA published updated support for its regional eCTD v4.0 Module 1 Implementation Guide and controlled vocabulary package in February 2025 and continues to accept submissions voluntarily, while signaling longer-term mandatory timelines. For regulatory affairs and submission publishers, this means updating XML backbones, metadata practices, validation tooling, and submission process controls now, and planning for the adoption of eCTD v4.0 across regulatory operations, regulatory information management (RIM), and submission publishing pipelines.

Why Module 1 matters now

Module 1 of the Common Technical Document (CTD) is unique: unlike Modules 2 through 5, which are harmonized internationally, Module 1 is region-specific and contains administrative, legal, and product information required by a particular health authority. Changes in Module 1, therefore, have an immediate operational impact for any sponsor filing in those jurisdictions. Over 2024 and 2025, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) issued important updates to how Module 1 should be packaged and validated, and those updates align with the broader industry shift to eCTD v4.0, the modernized format that emphasizes structured metadata and interoperability. This article explains what changed in 2025, why it matters for pharmaceutical manufacturers and regulatory affairs teams, what practical steps to take, and how to manage risk during the transition.

Executive summary of the 2025 changes

• EMA: The EU Module 1 eCTD Specification moved to version 3.1, with updated validation criteria v8.0. From 1 March 2025, only submissions conforming to EU M1 v3.1 and validation criteria v8.0 are accepted for new sequences by NCAs and EMA. This tightened acceptance window requires immediate compliance for sponsors submitting to the EU.
• FDA: In late February 2025, the FDA published updates to its regional eCTD v4.0 implementation package and controlled vocabulary, signaling increasing support for v4.0 Module 1 constructs, metadata schemas, and validation expectations. The FDA continues to accept v4.0 voluntarily while clarifying submission packaging, file-type specifications, and validation criteria.
• Industry: Surveys and vendor analyses show rising intent to migrate to eCTD v4.0, with many organizations planning migration within months to a few years. RIM market forecasts show strong growth driven by this transition, motivating investment in tooling and processes.

Deep dive: What the EMA changed in 2025 and why it matters

The EMA's EU Module 1 eCTD Specification v3.1 and validation criteria v8.0 represent the most immediate, mandatory change in the European region in early 2025. The key operational impacts are:

1. Validation criteria tightened and enforced from 1 March 2025. The EMA clarified technical validation expectations and released updated validation criteria to be used for all v3.1 eCTD submissions received on and after 1 March 2025. That change removed a prior acceptance window that allowed v3.0.4 and v3.1 submissions under mixed validation criteria; after March 1, only v3.1 + validation criteria v8.0 pass technical validation. For RA teams, the implication is non-negotiable: publisher toolchains and pre-submission checks must reflect the new criteria to avoid rejection at the validation gate.
2. Enhanced expectations for Module 1 content and tracking. EU Module 1 has explicit expectations for product information, national application forms, environmental risk assessments, and additional lifecycle documents such as responses to regulatory questions, rationale for variations, and renewal documentation. The updated specification reinforced the need for accurate Module 1 tracking tables and for clear document lifecycle handling, which aligns with modular eCTD practices but demands stricter attention to metadata and file placement. For multi-country filing strategies, sponsors must reconcile national procedural differences and ensure that Module 1 packaging maps precisely to each NCA's expectations.
3. Technical clarifications that reduce ambiguous packaging. The EU update is heavy on clarifications that reduce tolerance for ambiguous folder structures, inconsistent naming, or missing administrative forms. This practical tightening is aimed at improving automated validation throughput at NCAs, but it places a burden on sponsors to standardize publisher outputs and to upgrade validation tools. Vendors and in-house publishing teams must adopt the updated XML schemas and metadata conventions.

What the FDA changed in 2025 and how it relates to v4.0

The FDA's updates in early 2025 centered on support materials for eCTD v4.0 Module 1 and controlled vocabulary packages. The main points are:

1. FDA regional eCTD v4.0 Module 1 Implementation Guide v1.7 and controlled vocabulary package. On 27 February 2025, the FDA updated its regional controlled vocabulary package and Module 1 implementation guide (version v1.7), and published supporting specification updates. These updates provide clearer instructions for the FDA-regional XML elements that sit within Module 1 (for example, us-regional.xml). Practical impacts include updated allowed values for metadata fields, clarifications on administrative document placement, and updated validation criteria alignment with v4.0 practices. Sponsors submitting to the FDA should align their publisher outputs to the new implementation guide to reduce validation issues and to take advantage of improved metadata handling.
2. Continued voluntary acceptance with a road map to eventual mandate. The FDA has continued to accept eCTD v4.0 voluntarily while signaling broader industry timelines. Many industry analyses and vendor roadmaps point to a later mandatory date for v4.0, often cited as 2029, giving sponsors a runway to adopt but not to procrastinate. The key tactical guidance is to treat v4.0 readiness as a near-term priority (2025 to 2027) for testing, tooling upgrades, and pilot submissions while continuing to manage legacy v3.2.2 submission flows.
3. File-type and XML backbone clarifications. The FDA updated specifications on allowed file-format types and clarified expectations for XML backbone files for Module 1. Because the FDA's regional element includes administrative tags unique to the US, publishers must maintain compliance with both the ICH v4.0 spec for Modules 2 through 5 and the FDA regional guide for Module 1. Practical testing against FDA validation tools before submission is mandatory to avoid technical rejections.

Comparing EU and US changes: alignment and divergence

Although both authorities are tightening technical validations and encouraging structured metadata, their immediate priorities differ:

• Enforcement timing: EMA's Module 1 v3.1 plus validation criteria v8.0 has a hard enforcement date of 1 March 2025 for acceptance of new sequences. The FDA's updates in February 2025 focus on v4.0 support and controlled vocabularies but operate in a voluntary acceptance model with longer-term mandation discussions. Sponsors filing in both regions must prioritize the EU changes as immediately binding while simultaneously preparing for eventual full v4.0 readiness for the FDA.
• Metadata maturity: eCTD v4.0's strength is standardized machine-readable metadata and controlled vocabularies. The FDA's controlled vocabulary package and the EU's stricter validation criteria both push sponsors toward higher metadata quality. However, regional controlled vocabularies and administrative tags differ and must be mapped precisely where multi-region submissions are required.
• Validation tooling: both EMA and FDA changes increase reliance on automated validation. Sponsors need comprehensive pre-submission validation, ideally integrated into continuous publishing pipelines or RIM systems, to reduce last-minute rework and submission delays.

Industry adoption signals and market context

Multiple industry reports, surveys, and vendor commentaries in 2024, 2025 indicate accelerated industry interest in migrating to eCTD v4.0. A survey cited in industry literature reported that roughly three-quarters of respondents plan to migrate to eCTD, with an increased proportion planning near-term migration, which underscores the reality that many organizations are actively budgeting for this change. Meanwhile, the RIM market is projected to expand significantly as sponsors invest in tools to manage structured submission data, with a market forecast projecting multi-billion-dollar growth in the coming decade. These macro trends make it clear that publishers, RIM vendors, and regulatory operations functions must invest now.

Operational impact and risk areas for pharma manufacturing and pharma and medical device RA teams

The Module 1 changes have cascading operational impacts across several functions:

1. Submission publishing and XML engineering. Transitioning to v4.0 (or to updated Module 1 specs) requires updated publisher tools, mapping logic, and XML templates. The risk is mis-mapped administrative tags, missing controlled vocabulary values, or incorrect backbone files that cause validation failures. Mitigation: Validate early in a staging environment against the latest validation criteria and maintain a test harness that mirrors the NCA validation engines.
2. Regulatory information management and metadata hygiene. RIM systems must capture the new metadata fields and controlled vocabulary selections so that exports into package publishers produce compliant outputs. Without RIM alignment, publishers will need manual workarounds that are error-prone. Mitigation: inventory metadata gaps, update data models, and run reconciliation checks between RIM exports and the publisher outputs.
3. Labeling, national forms, and country-specific documents. Module 1 continues to host national application forms, labeling versions, and other region-specific content. The new EU validation criteria and FDA regional tags emphasize correct placement and consistency across documents. Mitigation: centralize labeling assets, version control across national texts, and automate Module 1 tracking tables.
4. Vendor and partner coordination. Many sponsors rely on third-party publishers either offshore or via cloud vendors. Contractual alignment must include obligations to update to the latest Module 1 specs, run pre-submission validations, and respond to NCAs' validation errors promptly. Mitigation: update SLAs, hold quarterly readiness checks, and require vendor evidence of tool compatibility.

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

Practical checklist: preparing for Module 1 compliance in 2025 and beyond

This checklist converts the regulatory changes into concrete actions.

1. Immediately update publisher toolchains to support EU M1 v3.1 and validation criteria v8.0 for any EU filings on/after 1 March 2025. Validate with EMA tools before sequence submission.
2. For US submissions, review the FDA regional eCTD v4.0 Module 1 Implementation Guide v1.7 and controlled vocabulary package published Feb 27, 2025; update mapping and pre-validation workflows.
3. Audit RIM data models to ensure new metadata fields and controlled vocabulary values are captured and enforced at the point of data capture.
4. Run end-to-end publisher tests with a staging NCA validator; test both v3.2.2 and v4.0 output modes to maintain parallel readiness for dual workflows.
5. Centralize Module 1 assets and tracking tables to support repeatable and auditable submission packaging.
6. Update contracts with external publishers to include requirements for specification updates and validation evidence.

Case example: a multi-national marketing application

Consider a sponsor filing a variation for the same product across EU member states and the US. The EU expects v3.1 packaging with validation criteria v8.0 as of 1 March 2025. The US expects outputs compatible with the updated regional v4.0 guide. The sponsor must therefore ensure that:

• Document naming and lifecycle annotations are consistent for reuse across modules.
• The RIM system captures national labeling variations and application forms.
• The publisher can emit both EU M1 v3.1 and FDA regional XML constructs without manual edits.
Failure to synchronize will lead to delays, correction cycles, and potentially missed regulatory windows. The good news is that modern publisher platforms and RIM tools increasingly support multi-target export from a single data model, but organizations must test and prove the path.

Measuring success: KPIs and validation metrics

To manage the transition, regulatory and publishing teams should track specific KPIs:

• Pre-validation pass rate: percentage of sequences that pass internal validation without errors.
• First-pass acceptance rate at NCAs: sequences accepted on first technical validation.
• Time-to-fix validation errors: median hours/days to resolve validation rejections.
• Metadata completeness score: percentage of required Module 1 metadata fields populated in RIM.
Tracking these KPIs provides measurable insight into whether the updated processes and tooling are effective. Vendors and in-house teams should set aggressive targets for improvement during the 2025 transition window.

Strategic considerations for longer-term eCTD v4.0 readiness

The Module 1 changes in 2025 are symptomatic of a larger shift toward the structured, metadata-rich world of eCTD v4.0. Strategic steps include:

• Treat eCTD v4.0 as a data modernization project, not just a file-format change. The goal is to make submission data reusable, queryable, and auditable across product lifecycle systems.
• Invest in RIM and API-enabled publisher toolchains so Module 1 metadata flows automatically from source systems into submission packages. This reduces manual hand-offs and errors.
• Run pilot v4.0 submissions in supportive jurisdictions, document lessons learned, and scale processes incrementally. The FDA's voluntary acceptance window is an opportunity to pilot.

Common pitfalls and how to avoid them

• Pitfall: Relying on ad-hoc manual edits to Module 1 files.
Fix: Automate metadata population and enforce validation rules at the data-entry point.

• Pitfall: Delayed vendor upgrades and mismatched SLAs.
Fix: Contractually require specification-compliant releases and validation evidence.

• Pitfall: Treating v4.0 as purely technical.
Fix: Reframe as a process and data improvement that requires cross-functional governance.